rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
2005-9-12
|
pubmed:abstractText |
We have shown that non-small cell lung cancer (NSCLC) is resistant to the histone deacetylase inhibitor (HDI) suberoylanilide hydroxamic acid (SAHA) through upregulation of the antiapoptotic transcription factor nuclear factor-kappaB (NF-kappaB). HDIs also promote chromatin remodeling, potentially making the DNA more accessible to chemotherapy. We hypothesize that combined SAHA and gemcitabine sensitizes NSCLC to apoptosis.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0039-6060
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
138
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
360-7
|
pubmed:dateRevised |
2008-5-30
|
pubmed:meshHeading |
pubmed-meshheading:16153448-Acetylation,
pubmed-meshheading:16153448-Antimetabolites, Antineoplastic,
pubmed-meshheading:16153448-Antineoplastic Agents,
pubmed-meshheading:16153448-Apoptosis,
pubmed-meshheading:16153448-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:16153448-Cell Line, Tumor,
pubmed-meshheading:16153448-Cell Survival,
pubmed-meshheading:16153448-Chromatin,
pubmed-meshheading:16153448-Deoxycytidine,
pubmed-meshheading:16153448-Drug Synergism,
pubmed-meshheading:16153448-Humans,
pubmed-meshheading:16153448-Hydroxamic Acids,
pubmed-meshheading:16153448-Lung Neoplasms,
pubmed-meshheading:16153448-NF-kappa B,
pubmed-meshheading:16153448-Transcription, Genetic
|
pubmed:year |
2005
|
pubmed:articleTitle |
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
|
pubmed:affiliation |
Department of Surgery, University of Virginia School of Medicine, Charlottesville 22908-0679, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, N.I.H., Extramural
|